BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 18, 2004
View Archived Issues
Stressgen's HspE7 Positive In Cervical Dysplasia Study
Demonstrating a 40 percent response rate in high-grade cervical dysplasia patients, Stressgen Biotechnologies Corp.'s lead candidate, HspE7, appears to be heading toward another Phase III trial. (BioWorld Today)
Read More
Committee Probes Flu Vaccine Shortage, Seeks Plan For 2005
Read More
Histone Deacetylases Put Bone Formation Control On To-Do List
Read More
IBM, United Devices Supporting Human Proteome Folding Project
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More